Despite shortcomings, contrast-enhanced MR angiography prevailed over digital subtraction angiography often enough in a head-to-head trial to become the modality of choice for investigations of suspected infrapopliteal occlusive disease at New York-Weill Cornell Medical Center.
Despite shortcomings, contrast-enhanced MR angiography prevailed over digital subtraction angiography often enough in a head-to-head trial to become the modality of choice for investigations of suspected infrapopliteal occlusive disease at New York-Weill Cornell Medical Center.
Dr. Honglei Zhang, a radiologist at Weill, laid out the rationale for revisions to her department's policy at the International Society for Magnetic Resonance in Medicine meeting in Miami. Her study of 52 patients produced almost identical results for 2D projection MRA performed on a 1.5T scanner and DSA exams for the popliteal arteries. MRA was less robust for detecting occlusive arterial disease in the feet.
The overall sensitive and specificity of MRA to significant stenosis were 84% and 95%, respectively, in the calf and 79% and 71% in the foot. For arterial occlusion, the sensitivity and specificity of MRA rose to 89% and 95%, respectively, in the calf and 79% and 86% in the foot.
"In the calf, MRA tends to undergrade the severity, but in the foot, the possibility of undergrading and overgrading is nearly identical," Zhang said.
A reexamination of the 105 instances in which DSA and MRA disagreed found the differences in physician interpretation in 43 segments came from borderline lesions that could easily be graded either way, she said. In 22 segments, the reviewers decided MRA was more likely to be correct than DSA. DSA image quality was poor in three of those instances and suffered inadequate x-ray contrast opacification in the rest.
"This indicates that DSA is not perfect as a gold standard, and the real accuracy of MRA may be higher than was shown here," Zhang said.
The accuracy of MRA, especially in smaller distal vessels, may improve as better acquisition techniques such as 3D TRICKS and VIPR and better reconstruction techniques are introduced, she said.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.